The Future of Pharmaceutical and Biopharmaceutical Manufacturing
A panel discussion moderated by Laura Bush, Editor in Chief of BioPharm International.
When: March 17, 2009
11:30 am - 12:45 pm
Where: Interphex 2009
The Jacob Javits Convention Center
New York, NY
The pressures on the pharmaceutical industry - expiring patents, falling profits resulting from drug safety problems, and now, the economic slump - affect manufacturing operations today more than ever. As a result, manufacturing organizations must find ways to reduce costs without sacrificing quality, whether by improving process efficiency through technology and operational excellence or through outsourcing. At the same time, regulatory expectations for quality are increasing, and initiatives such as Quality by Design are encouraging many companies to invest more, not less, in process development and manufacturing process control.
G. Steven Burrill will kick off this session by presenting his vision of the future of healthcare and the overriding trends affecting the global industry. His presentation will be followed by a panel discussion with senior executives from manufacturing organizations at Big Pharma and Big Biotech companies about how they are handling the major concerns affecting their organizations and what they envision for the future of pharmaceutical manufacturing. The discussion will cover topics such as:
Manufacturing economics - from technologies to improve efficiencies to operational excellence
Managing supply chain risk - from concerns about managing capacity forecasting to threats to raw material quality
Quality by Design - what companies are doing to improve manufacturing science and process control, and what kinds of investments are required
Outsourcing Strategies - Is Big Pharma shifting its focus from manufacturing to sourcing? And is everything moving to Asia?